Artelo Biosciences (ARTL) director gets 292 stock options in new grant

Rhea-AI Filing Summary

Artelo Biosciences director Gregory Reyes received a small stock option grant. On January 30, 2026, he was awarded options to buy 292 shares of Artelo Biosciences common stock at an exercise price of $1.71 per share, held directly. These options vest 100% on the earlier of January 30, 2027 or the day before the next annual shareholder meeting, as long as he continues serving the company.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Reyes Gregory

(Last) (First) (Middle)

C/O ARTELO BIOSCIENCES, INC.

505 LOMAS SANTA FE, SUITE 160

(Street)

SOLANA BEACH CA 92075

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ARTELO BIOSCIENCES, INC. [ ARTL ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/30/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$1.71	01/30/2026		A		292		(1)	01/30/2036	Common Stock	292	$0.00	292	D

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as such term is defined in the Issuer's Plan) through each such applicable vesting date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Vesting Commencement Date, or (ii) the day prior to the date of the annual meeting of the Issuer's stockholders next following the Vesting Commencement Date. "Vesting Commencement Date" shall mean January 30, 2026.

Remarks:

	/s/ Gregory D. Gorgas, as Attorney-in-Fact	02/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Artelo Biosciences (ARTL) report for Gregory Reyes?

Artelo Biosciences reported that director Gregory Reyes received stock options for 292 shares on January 30, 2026. These are derivative securities giving him the right to buy common stock at a fixed exercise price, subject to the disclosed vesting conditions.

How many Artelo Biosciences (ARTL) stock options were granted to Gregory Reyes?

Gregory Reyes was granted stock options covering 292 shares of Artelo Biosciences common stock. The filing shows he beneficially owns 292 derivative securities following the transaction, all held directly in his name according to the reported ownership details.

What is the exercise price of Gregory Reyes’ Artelo Biosciences (ARTL) stock options?

The stock options granted to Gregory Reyes have an exercise price of $1.71 per share. This means he can purchase Artelo Biosciences common stock at $1.71 for each optioned share once the options vest and before they expire.

When do Gregory Reyes’ Artelo Biosciences (ARTL) stock options vest?

All 292 options vest 100% on the earlier of January 30, 2027, or the day before Artelo Biosciences’ next annual shareholder meeting after January 30, 2026. Vesting requires that he continue as a service provider to the company through that date.

What is the expiration date of Gregory Reyes’ stock options in Artelo Biosciences (ARTL)?

The stock options granted to Gregory Reyes expire on January 30, 2036. Up to that expiration date, and after vesting, he may choose to exercise the options to purchase Artelo Biosciences common shares at the fixed $1.71 exercise price.

Is Gregory Reyes’ Artelo Biosciences (ARTL) option grant a direct or indirect holding?

The Form 4 shows Gregory Reyes’ 292 stock options as a direct holding. The ownership form is listed as “D” for direct, and there is no indication of any trust, LLC, or other entity holding these options on his behalf.